glycerol has been researched along with Diabetes Mellitus, Type 2 in 161 studies
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| "To compare the performance of population-based kinetics with that of directly measured C-peptide kinetics when used to calculate β-cell responsivity indices, and to study people with and without acute insulin resistance to ensure that population-based kinetics apply to all conditions where β-cell function is measured." | 7.88 | Performance of individually measured vs population-based C-peptide kinetics to assess β-cell function in the presence and absence of acute insulin resistance. ( Bailey, KR; Cobelli, C; Dalla Man, C; Laurenti, MC; Piccinini, F; Rizza, RA; Shah, M; Sharma, A; Varghese, RT; Vella, A, 2018) |
| "We investigated the association of fasting serum glycerol and fatty acids (FAs) as predictors for worsening of hyperglycemia and incident type 2 diabetes." | 7.79 | Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. ( Ala-Korpela, M; Cederberg, H; Kangas, AJ; Kuusisto, J; Laakso, M; Mahendran, Y; Soininen, P; Uusitupa, M; Vangipurapu, J, 2013) |
| "The objective was to assess glucose, lactate, glycerol, and pyruvate concentrations in the interstitial fluid of the adipose tissue as well as the glucose relative recovery coefficient in reference to capillary blood (RC) during the first two days of the standard treatment of diabetic ketoacidosis (DKA) in patients with type 1 and type 2 diabetes." | 7.79 | Microdialysis monitoring of glucose, lactate, glycerol, and pyruvate in patients with diabetic ketoacidosis. ( Ciechanowska, A; Foltynski, P; Karnafel, W; Kawiak, J; Krzymien, J; Ladyzynski, P; Pulawska, E; Sabalinska, S; Wojcicki, JM, 2013) |
| "We sought to determine whether pioglitazone and metformin alter NEFA-induced insulin resistance in type 2 diabetes and, if so, the mechanism whereby this is effected." | 7.74 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes. ( Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P, 2008) |
| "The rate of lipolysis (glycerol Ra), gluconeogenesis from glycerol, and its contribution to overall hepatic glucose production (glucose Ra) were determined in 10 patients with noninsulin-dependent diabetes mellitus (NIDDM) [body mass index (BMI) 27." | 7.68 | Lipolysis and gluconeogenesis from glycerol are increased in patients with noninsulin-dependent diabetes mellitus. ( Koivisto, VA; Puhakainen, I; Yki-Järvinen, H, 1992) |
| "Most people with both conditions have type 2 diabetes, but it is unknown if type 1 and type 2 diabetes have identical effects on tuberculosis susceptibility." | 5.91 | Glycerol contributes to tuberculosis susceptibility in male mice with type 2 diabetes. ( Bellerose, M; Cavallo, K; Jameson, ML; Kornfeld, H; Martinez, N; Sassetti, CM; Singhal, A; Smith, CM; Smulan, LJ; West, K; Williams, J, 2023) |
| "To examine whether the circulating substrate mix may be related to the incidence of heart failure (HF) and cardiovascular (CV) mortality and how it is altered by canagliflozin treatment." | 5.51 | Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). ( Baldi, S; Ferrannini, E; Figtree, GA; Hansen, MK; Mahaffey, KW; Neal, B; Perkovic, V; Rosenthal, N; Scozzaro, T; Shaw, W; Tesfaye, F; Tsimihodimos, V, 2022) |
| "Our objective was to investigate the effects of roflumilast on glucose homeostasis and body weight." | 5.16 | Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. ( Bredenbröker, D; Brose, M; Fabbri, LM; Göke, B; Rabe, KF; Teichmann, P; Wouters, EF, 2012) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| " The objectives of the present review were to discuss some genes that potentially modulate the risk of coronary artery disease in diabetes mellitus; to address how the genes' respective contributions could possibly influence the global risk assessment of coronary artery disease among diabetic patients; and to present simple clinical markers, such as plasma glycerol concentration and the 'hypertriglyceridemic waist' phenotype, that could help to identify high-risk individuals." | 4.82 | Genetic aspects of diabetes and its cardiovascular complications: contribution of genetics to risk assessment and clinical management. ( Després, JP; Gaudet, D; Poirier, P; St-Pierre, J; Vohl, MC, 2005) |
| " Considering the clinical diagnosis of glycerol-induced hemolysis and acute kidney injury, intravenous hydration and haptoglobin administration were started, which successfully treated the dark red urine and renal dysfunction." | 3.96 | Acute Kidney Injury with Hemolysis after Glycerin Enema-induced Rectal Injury in a Patient with Type 2 Diabetes. ( Furuya, F; Harima, N; Hayashida, R; Ichijo, M; Kitamura, K; Nakamura, S; Tsuchiya, K, 2020) |
| "To compare the performance of population-based kinetics with that of directly measured C-peptide kinetics when used to calculate β-cell responsivity indices, and to study people with and without acute insulin resistance to ensure that population-based kinetics apply to all conditions where β-cell function is measured." | 3.88 | Performance of individually measured vs population-based C-peptide kinetics to assess β-cell function in the presence and absence of acute insulin resistance. ( Bailey, KR; Cobelli, C; Dalla Man, C; Laurenti, MC; Piccinini, F; Rizza, RA; Shah, M; Sharma, A; Varghese, RT; Vella, A, 2018) |
| " Serum FFA (n = 3,306), plasma glycerol (n = 3,776), and insulin sensitivity index (HOMA-IR,n = 3,469) were determined." | 3.81 | Fatty Acids, Obesity and Insulin Resistance. ( Arner, P; Rydén, M, 2015) |
| "We investigated the association of fasting serum glycerol and fatty acids (FAs) as predictors for worsening of hyperglycemia and incident type 2 diabetes." | 3.79 | Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. ( Ala-Korpela, M; Cederberg, H; Kangas, AJ; Kuusisto, J; Laakso, M; Mahendran, Y; Soininen, P; Uusitupa, M; Vangipurapu, J, 2013) |
| "The objective was to assess glucose, lactate, glycerol, and pyruvate concentrations in the interstitial fluid of the adipose tissue as well as the glucose relative recovery coefficient in reference to capillary blood (RC) during the first two days of the standard treatment of diabetic ketoacidosis (DKA) in patients with type 1 and type 2 diabetes." | 3.79 | Microdialysis monitoring of glucose, lactate, glycerol, and pyruvate in patients with diabetic ketoacidosis. ( Ciechanowska, A; Foltynski, P; Karnafel, W; Kawiak, J; Krzymien, J; Ladyzynski, P; Pulawska, E; Sabalinska, S; Wojcicki, JM, 2013) |
| "Curcumin, an active component derived from dietary spice turmeric (Curcuma longa), has been demonstrated antihyperglycemic, antiinflammatory and hypocholesterolemic activities in obesity and diabetes." | 3.78 | Curcumin attenuates lipolysis stimulated by tumor necrosis factor-α or isoproterenol in 3T3-L1 adipocytes. ( Kong, PR; Li, Y; Li, YX; Wu, JF; Xie, XY, 2012) |
| " Glycerol in T2DM microdialysate (but not in T1DM) was higher than in healthy volunteers, which is likely explained by sc insulin resistance (insulin is a potent antilipolytic hormone)." | 3.76 | Analyte flux at a biomaterial-tissue interface over time: implications for sensors for type 1 and 2 diabetes mellitus. ( Adamson, U; Brismar, K; Ekberg, NR; Hedblad, MA; Malmstedt, J; Ungerstedt, U; Wisniewski, N, 2010) |
| "We sought to determine whether pioglitazone and metformin alter NEFA-induced insulin resistance in type 2 diabetes and, if so, the mechanism whereby this is effected." | 3.74 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes. ( Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P, 2008) |
| " g body wt-1 for each administration), failed to prevent the fall in body weight, liver and muscle glycogen contents, and plasma d-glucose or insulin concentration, as well as the increase in plasma free fatty acid and beta-hydroxybutyrate concentrations caused by starvation." | 3.70 | Assessment of the nutritional value of glycerol-1,2, 3-tris(methylsuccinate) in fed and starved rats. ( Björkling, F; Ladrière, L; Malaisse, WJ, 1999) |
| "The rate of lipolysis (glycerol Ra), gluconeogenesis from glycerol, and its contribution to overall hepatic glucose production (glucose Ra) were determined in 10 patients with noninsulin-dependent diabetes mellitus (NIDDM) [body mass index (BMI) 27." | 3.68 | Lipolysis and gluconeogenesis from glycerol are increased in patients with noninsulin-dependent diabetes mellitus. ( Koivisto, VA; Puhakainen, I; Yki-Järvinen, H, 1992) |
| "Among this population with Type 2 diabetes high liver fat was associated with hyperinsulinemia, higher fasting glucose levels, peripheral and hepatic insulin resistance, and impaired suppression of FFA oxidation and FFA and glycerol turnover during hyperinsulinemia." | 2.79 | Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver. ( Andrew, R; Bastin, ME; Gray, CD; Iredale, JP; Macfarlane, DP; Marshall, I; Preston, T; Raubenheimer, PJ; Walker, BR, 2014) |
| " Sustained suppression of non-esterified fatty acid (NEFA) and glycerol concentrations was observed with all GSK256073 doses throughout the 48-h dosing period." | 2.78 | GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. ( Byerly, RL; Dobbins, RL; Gao, FF; Le Monnier de Gouville, AC; Mahar, KM; Nachbaur, GJ; Napolitano, A; Shearn, SP, 2013) |
| "Atenolol is a beta-1 adrenergic antagonist commonly prescribed for the treatment of systemic hypertension or coronary artery disease yet its use in individuals with type 2 diabetes mellitus (T2DM) is controversial due to potentially negative side effects on insulin resistance." | 2.77 | The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes. ( Brassard, P; Cianflone, K; Ferland, A; Lacroix, S; Méthot, J; Poirier, P; Smith, J, 2012) |
| "3 mOsm/l in the group of diabetic patients after the low and high dose, respectively, reflecting a dose-response relationship." | 2.74 | The effects of peroral glycerol on plasma osmolarity in diabetic patients and healthy individuals. ( la Cour, M; Lund-Andersen, H; Sander, B; Thornit, DN, 2009) |
| "Pioglitazone has been shown to reduce fasting triglyceride levels." | 2.74 | Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. ( Buzzigoli, E; Casolaro, A; Ciociaro, D; Ferrannini, E; Frascerra, S; Gastaldelli, A; Nannipieri, M, 2009) |
| "Thirty-one subjects with type 2 diabetes were randomly assigned to pioglitazone (45 mg) or metformin (2,000 mg) for 4 months." | 2.73 | Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. ( Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P, 2008) |
| "Glycerol concentration was 267 +/- 41 micromol/L and 133 +/- 40 micromol/L in PF and venous blood, respectively (P = 0." | 2.73 | Microdialysis technique as a monitoring system for acute complications of diabetes. ( Ciechanowska, A; Foltynski, P; Karnafel, W; Kawiak, J; Krzymien, J; Ladyzynski, P; Pulawska, E; Sabalinska, S; Wojcicki, JM, 2008) |
| "We propose that hyperglycemia is the driving force that aggravates overproduction of VLDL1 in DM2." | 2.71 | Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. ( Adiels, M; Borén, J; Caslake, MJ; Olofsson, SO; Packard, C; Soro, A; Stewart, P; Taskinen, MR; Wennberg, B; Westerbacka, J, 2005) |
| "Five adults with type 2 diabetes underwent an oral glucose tolerance test (OGTT) on two separate occasions, at least 1 week apart." | 2.70 | Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. ( Cherrington, AD; Davis, SN; Mann, SL; Moore, MC, 2001) |
| " Despite similar acipimox concentration on day 1 and day 4 of this frequent dosing regimen, the free fatty acid concentrations were significantly higher on day 4 compared with day 1 (P < 0." | 2.67 | Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. ( Groop, L; Härkönen, M; Melander, A; Saloranta, C; Taskinen, MR; Widen, E, 1993) |
| "Thus, in NIDDM, BAYm 1099 was effective in diminishing and delaying postprandial excursions of blood glucose, lactate, and pyruvate after high- and low-sucrose meals, but overall metabolic control remained unchanged." | 2.66 | Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo. ( Alberti, KG; Samad, AH; Taylor, R; Ty Willing, TS, 1988) |
| "Obesity is a major risk factor for insulin resistance and type 2 diabetes." | 2.44 | [Glyceroneogenesis and PEPCK-C: pharmacological targets in type 2 diabetes]. ( Benelli, C; Cadoudal, T; Forest, C; Fouque, F, 2008) |
| "Most people with both conditions have type 2 diabetes, but it is unknown if type 1 and type 2 diabetes have identical effects on tuberculosis susceptibility." | 1.91 | Glycerol contributes to tuberculosis susceptibility in male mice with type 2 diabetes. ( Bellerose, M; Cavallo, K; Jameson, ML; Kornfeld, H; Martinez, N; Sassetti, CM; Singhal, A; Smith, CM; Smulan, LJ; West, K; Williams, J, 2023) |
| "In people with type 2 diabetes (T2D), fasting hyperglycemia is greater in the morning (a." | 1.91 | Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage. ( Bolli, GB; De Fano, M; Fanelli, CG; Lucidi, P; Pampanelli, S; Perriello, G; Porcellati, F; Tura, A, 2023) |
| "Obesity is linked to cardiometabolic diseases, however non-obese individuals are also at risk for type 2 diabetes (T2D) and cardiovascular disease (CVD)." | 1.91 | Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4 ( Andersson, DP; Arner, P; Hofwimmer, K; Laurencikiene, J; Massier, L; Subramanian, N; Tavira, B, 2023) |
| "However, hyperinsulinemia is observed in subjects with normoglycaemia and thus the paradigm above should be reevaluated." | 1.62 | Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study. ( Becattini, B; Brogren, H; Fryk, E; Gan, LM; Jansson, PA; Lind, L; Mossberg, K; Olausson, J; Piazza, S; Provenzani, A; Schmelz, M; Solinas, G; Strindberg, L, 2021) |
| "type II diabetes and Alzheimer's disease) are characterised by amyloid deposition." | 1.62 | The kinetics of islet amyloid polypeptide phase-separated system and hydrogel formation are critically influenced by macromolecular crowding. ( Jean, L; Pytowski, L; Vaux, DJ, 2021) |
| "To assess its possible involvement in childhood obesity and metabolic abnormalities, the AQP7 promoter was studied in order to identify possible mutations and/or polymorphisms in children." | 1.56 | The metabolic implications of aquaporin 7 (AQP7) promoter variants in lean children and children with obesity. ( Georgiou, G; Kostopoulou, E; Oikonomou, E; Rojas-Gil, AP; Spiliotis, BE, 2020) |
| "Obesity is strongly related to type-2 diabetes (T2DM), but there is a subset of obese individuals that remains relatively insulin sensitive and metabolically healthy." | 1.40 | Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance. ( Berends, FJ; Ioan-Facsinay, A; Koning, F; Lips, MA; Pijl, H; Toes, R; van Beek, L; van Harmelen, V; Visser, A; Willems van Dijk, K, 2014) |
| "An artificial hyperinsulinemia, which was induced to delineate the potential interaction between elevated FFAs and hyperinsulinemia, revealed that hyperinsulinemia also increased FGF-21 levels in vivo, while rosiglitazone treatment had no effect." | 1.35 | Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. ( Andres, J; Biedasek, K; Bobbert, T; Clemenz, M; Kintscher, U; Mai, K; Meinus, S; Möhlig, M; Pfeiffer, AF; Reinecke, F; Sabath, M; Spranger, J; Spuler, S; Weicht, J; Weickert, MO, 2009) |
| "Obesity is a risk factor for type 2 diabetes in cats." | 1.35 | The impact of obesity, sex, and diet on hepatic glucose production in cats. ( Burgess, SC; Ferguson, DC; Glushka, J; Hoenig, M; Jin, ES; Jordan, ET; Kley, S; Olson, DE; Prestegard, JH; Waldron, M; Wu, S, 2009) |
| "Subjects with type 2 diabetes mellitus were studied before and after a 6-month behavioral intervention therapy, during fasting and during a hyperinsulinemic normoglycemic clamp." | 1.35 | Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans. ( Bugianesi, E; Hanson, RW; Kalhan, SC; Kelley, DE; McCullough, AJ, 2008) |
| "Obesity is a common and rapidly growing health problem today." | 1.35 | Human mesenteric adipose tissue plays unique role versus subcutaneous and omental fat in obesity related diabetes. ( Abrams, GA; Aprahamian, CJ; Chen, M; Clements, RH; Harmon, CM; Yang, YK, 2008) |
| "To assess mechanisms for postprandial hyperglycemia, we used a triple-isotope technique ([\\3-(3)H]glucose and [(14)C]bicarbonate and oral [6,6-dideutero]glucose iv) and indirect calorimetry to compare components of glucose release and pathways for glucose disposal in 26 subjects with type 2 diabetes and 15 age-, weight-, and sex-matched normal volunteers after a standard meal." | 1.33 | Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. ( Dostou, JM; Gerich, JE; Gosmanov, NR; Meyer, C; Szoke, E; Welle, SL; Wittlin, SD; Woerle, HJ, 2006) |
| "lean (n = 10) subjects and type 2 diabetes patients (n = 8) vs." | 1.31 | Measurements of interstitial muscle glycerol in normal and insulin-resistant subjects. ( Ekberg, K; Gudbjörnsdottir, S; Holmäng, A; Lönnroth, P; Sjöstrand, M; Strindberg, L, 2002) |
| "A total of 8 obese subjects with type 2 diabetes were studied while on a eucaloric diet and after reduced energy intake (25 and then 75% of requirements for 10 days each)." | 1.31 | Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes. ( Christiansen, MP; Hellerstein, MK; Linfoot, PA; Neese, RA, 2000) |
| "Glycerol release (GR) was used to assess the lipolytic rate and was highest in LW in the abdominal area [0 h: LW, 1." | 1.31 | Lactate and glycerol release from adipose tissue in lean, obese, and diabetic women from South Africa. ( Boyd, IH; Crowther, NJ; Gray, IP; Joffe, BI; Lönnroth, PN; Schlaphoff, GP; van der Merwe, MT, 2001) |
| "Rosiglitazone treatment resulted in a 68% (P < 0." | 1.31 | The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. ( Befroy, D; Cline, GW; Dufour, S; Enocksson, S; Hundal, RS; Inzucchi, SE; Lebon, V; Mayerson, AB; Petersen, KF; Shulman, GI, 2002) |
| "Glucose effectiveness is impaired in type 2 diabetes." | 1.31 | Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects. ( Gabriely, I; Hawkins, M; Reddy, K; Rossetti, L; Shamoon, H; Wozniak, R, 2002) |
| "Glycerol, which was present in the infused lipid (272 mmol/l) did not affect ISR." | 1.30 | Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. ( Boden, G; Chen, X, 1999) |
| "Thirteen patients with type 2 diabetes were studied (mean age 56." | 1.30 | Glucose and fatty acid metabolism in type 2 diabetes mellitus: an assessment using low-dose insulin infusion and the hyperinsulinaemic euglycaemic clamp. ( Nattrass, M; Smith, JM; Webber, J; Whitelaw, D, 1999) |
| "We conclude that in type 2 diabetes, both liver and kidney contribute to glucose overproduction and that renal glucose uptake is markedly increased." | 1.30 | Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. ( Dostou, J; Gerich, J; Meyer, C; Mitrakou, A; Nadkarni, V; Stumvoll, M, 1998) |
| "To evaluate the influence of NIDDM on subcutaneous adipose tissue metabolism microdialysis combined with 133Xe clearance and measurements in arterialized plasma were carried out using samples of subcutaneous abdominal fat from nine obese NIDDM subjects (glucose, 7." | 1.29 | Microdialysis assessment of adipose tissue metabolism in post-absorptive obese NIDDM subjects. ( Jansson, PA; Lönnroth, P; Smith, U, 1995) |
| "Type 2 diabetes is characterized by resistance to insulin action of glucose metabolism and lipolysis." | 1.29 | Insulin resistance with respect to lipolysis in non-diabetic relatives of European patients with type 2 diabetes. ( Anyaoku, V; Coldham, N; Gelding, SV; Johnston, DG; Niththyananthan, R, 1995) |
| "Insulin sensitivity was reduced in the Asian relatives compared to their controls (183 +/- 7 vs 139 +/- 12 mumol/l/min, P < 0." | 1.29 | Insulin sensitivity in non-diabetic relatives of patients with non-insulin-dependent diabetes from two ethnic groups. ( Chan, SP; Gelding, SV; Gray, IP; Johnston, DG; Mather, H; Niththyananthan, R; Robinson, S; Skinner, E, 1994) |
| " Significant linear dose-response relationships were found between plasma insulin (log) and glucose, TKB (log), NEFA, and glycerol concentrations by analysis of variance applied to regression (all P < 0." | 1.29 | Insulin resistance in the regulation of lipolysis and ketone body metabolism in non-insulin dependent diabetes is apparent at very low insulin concentrations. ( Krentz, AJ; Nattrass, M; Singh, BM, 1993) |
| "Six patients with type 2 diabetes underwent detailed metabolic studies before and after a minimum of 3 months' glibenclamide therapy." | 1.29 | The effects of glibenclamide on glucose homeostasis and lipoprotein metabolism in poorly controlled type 2 diabetes. ( Baynes, C; Elkeles, RS; Henderson, AD; Johnston, DG; Richmond, W, 1993) |
| "Nine male patients with NIDDM (age 53 +/- 2 years [mean +/- SE]; BMI 30." | 1.29 | The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. ( Andersson, OK; Gudbjörnsdóttir, HS; Jansson, PA; Lönnroth, PN, 1996) |
| "Patients with Type 2 diabetes had higher basal concentrations of both glycerol (81 +/- 7 (+/- SE) vs 61 +/- 7 mumol l-1, p less than 0." | 1.28 | Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes. ( Chen, YD; Hollenbeck, CB; Reaven, GM; Skowronski, R; Varasteh, BB, 1991) |
| "Fourteen patients with NIDDM (mean +/- SE age 61 +/- 2 yr, fasting plasma glucose 11." | 1.28 | No reduction in total hepatic glucose output by inhibition of gluconeogenesis with ethanol in NIDDM patients. ( Koivisto, VA; Puhakainen, I; Yki-Järvinen, H, 1991) |
| "In untreated NIDDM oral glucose induced a significant (p less than 0." | 1.27 | Antilipolytic effect of insulin in non-insulin-dependent diabetes mellitus after conventional treatment with diet and sulfonylurea. ( Arner, P; Bolinder, J, 1988) |
| "The metformin dosage was 1 g twice daily in 9 of the patients and 850 mg thrice daily in the 10th subject." | 1.27 | Mechanism of metformin action in non-insulin-dependent diabetes. ( Disilvio, L; Featherbe, D; Hawa, MI; Jackson, RA; Jaspan, JB; Kurtz, AB; Sim, BM, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (9.32) | 18.7374 |
| 1990's | 52 (32.30) | 18.2507 |
| 2000's | 48 (29.81) | 29.6817 |
| 2010's | 29 (18.01) | 24.3611 |
| 2020's | 17 (10.56) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrannini, E | 2 |
| Baldi, S | 1 |
| Scozzaro, T | 1 |
| Tsimihodimos, V | 1 |
| Tesfaye, F | 1 |
| Shaw, W | 1 |
| Rosenthal, N | 1 |
| Figtree, GA | 1 |
| Neal, B | 1 |
| Mahaffey, KW | 1 |
| Perkovic, V | 1 |
| Hansen, MK | 1 |
| Lu, Y | 3 |
| Li, J | 8 |
| Ji, J | 1 |
| Nie, X | 1 |
| Yu, N | 1 |
| Meng, X | 2 |
| Chiu, HC | 3 |
| Yang, RS | 3 |
| Weng, TI | 3 |
| Chiu, CY | 3 |
| Lan, KC | 3 |
| Liu, SH | 3 |
| Rani, RM | 1 |
| Syngkli, S | 1 |
| Nongkhlaw, J | 1 |
| Das, B | 1 |
| Subramanian, N | 1 |
| Hofwimmer, K | 1 |
| Tavira, B | 1 |
| Massier, L | 1 |
| Andersson, DP | 1 |
| Arner, P | 4 |
| Laurencikiene, J | 1 |
| Lucidi, P | 1 |
| Perriello, G | 1 |
| Porcellati, F | 1 |
| Pampanelli, S | 1 |
| De Fano, M | 1 |
| Tura, A | 1 |
| Bolli, GB | 1 |
| Fanelli, CG | 1 |
| Martinez, N | 1 |
| Smulan, LJ | 1 |
| Jameson, ML | 1 |
| Smith, CM | 1 |
| Cavallo, K | 1 |
| Bellerose, M | 1 |
| Williams, J | 1 |
| West, K | 1 |
| Sassetti, CM | 1 |
| Singhal, A | 1 |
| Kornfeld, H | 1 |
| Oikonomou, E | 1 |
| Kostopoulou, E | 1 |
| Rojas-Gil, AP | 1 |
| Georgiou, G | 1 |
| Spiliotis, BE | 1 |
| Hayashida, R | 1 |
| Tsuchiya, K | 1 |
| Nakamura, S | 1 |
| Harima, N | 1 |
| Ichijo, M | 1 |
| Furuya, F | 1 |
| Kitamura, K | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 6 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 2 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 4 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 4 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 4 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 6 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Li, W | 3 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 2 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Yan, R | 1 |
| Zhang, Y | 6 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 8 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 7 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 2 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 6 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 2 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 5 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 3 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 2 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 1 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 2 |
| Wu, J | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 2 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Rajala, A | 1 |
| Soni, K | 1 |
| Rajala, RVS | 1 |
| Neeland, IJ | 1 |
| de Albuquerque Rocha, N | 1 |
| Hughes, C | 1 |
| Ayers, CR | 1 |
| Malloy, CR | 2 |
| Jin, ES | 3 |
| Hædersdal, S | 1 |
| Lund, A | 1 |
| Nielsen-Hannerup, E | 1 |
| Maagensen, H | 1 |
| van Hall, G | 1 |
| Holst, JJ | 2 |
| Knop, FK | 2 |
| Vilsbøll, T | 1 |
| Fryk, E | 1 |
| Olausson, J | 1 |
| Mossberg, K | 1 |
| Strindberg, L | 2 |
| Schmelz, M | 1 |
| Brogren, H | 1 |
| Gan, LM | 1 |
| Piazza, S | 1 |
| Provenzani, A | 1 |
| Becattini, B | 1 |
| Lind, L | 1 |
| Solinas, G | 1 |
| Jansson, PA | 3 |
| Tully, M | 1 |
| Wedepohl, S | 1 |
| Kutifa, D | 1 |
| Weise, C | 1 |
| Licha, K | 1 |
| Schirner, M | 1 |
| Haag, R | 1 |
| Pytowski, L | 1 |
| Vaux, DJ | 1 |
| Jean, L | 1 |
| Schumann, U | 1 |
| Jenkinson, CP | 1 |
| Alt, A | 1 |
| Zügel, M | 1 |
| Steinacker, JM | 1 |
| Flechtner-Mors, M | 1 |
| Varghese, RT | 1 |
| Dalla Man, C | 1 |
| Laurenti, MC | 1 |
| Piccinini, F | 1 |
| Sharma, A | 1 |
| Shah, M | 1 |
| Bailey, KR | 1 |
| Rizza, RA | 3 |
| Cobelli, C | 1 |
| Vella, A | 1 |
| Chen, B | 1 |
| Ji, T | 1 |
| Pendharkar, SA | 1 |
| Singh, RG | 1 |
| Petrov, MS | 1 |
| Mandøe, MJ | 1 |
| Hansen, KB | 1 |
| Windeløv, JA | 1 |
| Rehfeld, JF | 1 |
| Rosenkilde, MM | 1 |
| Hansen, HS | 1 |
| La Han, B | 1 |
| Guan, Q | 1 |
| Chafeeva, I | 1 |
| Mendelson, AA | 1 |
| da Roza, G | 1 |
| Liggins, R | 1 |
| Kizhakkedathu, JN | 1 |
| Du, C | 1 |
| Dobbins, RL | 1 |
| Shearn, SP | 1 |
| Byerly, RL | 1 |
| Gao, FF | 1 |
| Mahar, KM | 1 |
| Napolitano, A | 1 |
| Nachbaur, GJ | 1 |
| Le Monnier de Gouville, AC | 1 |
| Rajpal, A | 1 |
| Dube, S | 1 |
| Carvalho, F | 1 |
| Simoes, AR | 1 |
| Figueiredo, A | 1 |
| Basu, A | 3 |
| Jones, J | 1 |
| Basu, R | 3 |
| Mahendran, Y | 1 |
| Cederberg, H | 1 |
| Vangipurapu, J | 1 |
| Kangas, AJ | 1 |
| Soininen, P | 1 |
| Kuusisto, J | 1 |
| Uusitupa, M | 1 |
| Ala-Korpela, M | 1 |
| Laakso, M | 1 |
| Ciechanowska, A | 2 |
| Ladyzynski, P | 2 |
| Wojcicki, JM | 2 |
| Sabalinska, S | 2 |
| Krzymien, J | 2 |
| Pulawska, E | 2 |
| Karnafel, W | 2 |
| Foltynski, P | 2 |
| Kawiak, J | 2 |
| van Beek, L | 1 |
| Lips, MA | 1 |
| Visser, A | 1 |
| Pijl, H | 1 |
| Ioan-Facsinay, A | 1 |
| Toes, R | 1 |
| Berends, FJ | 1 |
| Willems van Dijk, K | 1 |
| Koning, F | 1 |
| van Harmelen, V | 1 |
| Macfarlane, DP | 1 |
| Raubenheimer, PJ | 1 |
| Preston, T | 1 |
| Gray, CD | 1 |
| Bastin, ME | 1 |
| Marshall, I | 1 |
| Iredale, JP | 1 |
| Andrew, R | 1 |
| Walker, BR | 1 |
| Ferrer, R | 1 |
| Pardina, E | 1 |
| Rossell, J | 1 |
| Baena-Fustegueras, JA | 1 |
| Lecube, A | 1 |
| Balibrea, JM | 1 |
| Caubet, E | 1 |
| González, O | 1 |
| Vilallonga, R | 1 |
| Fort, JM | 1 |
| Peinado-Onsurbe, J | 1 |
| Kase, ET | 1 |
| Feng, YZ | 1 |
| Badin, PM | 1 |
| Bakke, SS | 1 |
| Laurens, C | 1 |
| Coue, M | 1 |
| Langin, D | 3 |
| Gaster, M | 1 |
| Thoresen, GH | 1 |
| Rustan, AC | 1 |
| Moro, C | 1 |
| Federici, A | 2 |
| Federici, G | 2 |
| Milani, M | 2 |
| Rydén, M | 1 |
| DiPilato, LM | 1 |
| Ahmad, F | 1 |
| Harms, M | 1 |
| Seale, P | 1 |
| Manganiello, V | 1 |
| Birnbaum, MJ | 1 |
| Laforenza, U | 1 |
| Bottino, C | 1 |
| Gastaldi, G | 1 |
| Pyle, L | 1 |
| Bergman, BC | 1 |
| Nadeau, KJ | 1 |
| Cree-Green, M | 1 |
| Karstoft, K | 1 |
| Wallis, GA | 1 |
| Pedersen, BK | 2 |
| Solomon, TP | 1 |
| Ong, CN | 1 |
| Subramaniam, T | 1 |
| Choi, HW | 1 |
| Yuan, JM | 1 |
| Koh, WP | 1 |
| Pan, A | 1 |
| Chandramouli, V | 2 |
| Norby, B | 2 |
| Dicke, B | 2 |
| Shah, P | 2 |
| Cohen, O | 2 |
| Landau, BR | 2 |
| Davis, SN | 4 |
| Mann, S | 1 |
| Briscoe, VJ | 1 |
| Ertl, AC | 1 |
| Tate, DB | 1 |
| Yang, YK | 1 |
| Chen, M | 1 |
| Clements, RH | 1 |
| Abrams, GA | 1 |
| Aprahamian, CJ | 1 |
| Harmon, CM | 1 |
| Kley, S | 1 |
| Hoenig, M | 1 |
| Glushka, J | 1 |
| Burgess, SC | 2 |
| Waldron, M | 1 |
| Jordan, ET | 1 |
| Prestegard, JH | 1 |
| Ferguson, DC | 1 |
| Olson, DE | 1 |
| Mai, K | 1 |
| Andres, J | 1 |
| Biedasek, K | 1 |
| Weicht, J | 1 |
| Bobbert, T | 1 |
| Sabath, M | 1 |
| Meinus, S | 1 |
| Reinecke, F | 1 |
| Möhlig, M | 1 |
| Weickert, MO | 1 |
| Clemenz, M | 1 |
| Pfeiffer, AF | 1 |
| Kintscher, U | 1 |
| Spuler, S | 1 |
| Spranger, J | 1 |
| Gastaldelli, A | 1 |
| Casolaro, A | 1 |
| Ciociaro, D | 1 |
| Frascerra, S | 1 |
| Nannipieri, M | 1 |
| Buzzigoli, E | 1 |
| Szabó, Z | 3 |
| Andersson, RG | 1 |
| Arnqvist, HJ | 1 |
| Thornit, DN | 1 |
| Sander, B | 1 |
| la Cour, M | 1 |
| Lund-Andersen, H | 1 |
| Ekberg, NR | 1 |
| Brismar, K | 2 |
| Malmstedt, J | 1 |
| Hedblad, MA | 1 |
| Adamson, U | 1 |
| Ungerstedt, U | 2 |
| Wisniewski, N | 1 |
| Smith, J | 1 |
| Ferland, A | 1 |
| Méthot, J | 1 |
| Brassard, P | 2 |
| Lacroix, S | 1 |
| Poirier, P | 2 |
| Cianflone, K | 1 |
| Mittendorfer, B | 1 |
| Horowitz, JF | 1 |
| DePaoli, AM | 1 |
| McCamish, MA | 1 |
| Patterson, BW | 3 |
| Klein, S | 1 |
| Wouters, EF | 1 |
| Bredenbröker, D | 1 |
| Teichmann, P | 1 |
| Brose, M | 1 |
| Rabe, KF | 1 |
| Fabbri, LM | 1 |
| Göke, B | 1 |
| Scherer, T | 1 |
| Lindtner, C | 1 |
| Zielinski, E | 1 |
| O'Hare, J | 1 |
| Filatova, N | 1 |
| Buettner, C | 1 |
| Xie, XY | 1 |
| Kong, PR | 1 |
| Wu, JF | 1 |
| Li, YX | 1 |
| Guan, HP | 1 |
| Jensen, MV | 1 |
| Newgard, CB | 1 |
| Steppan, CM | 1 |
| Lazar, MA | 1 |
| Stingl, H | 1 |
| Raffesberg, W | 1 |
| Nowotny, P | 1 |
| Waldhäusl, W | 1 |
| Roden, M | 1 |
| Tan, GD | 2 |
| Debard, C | 1 |
| Tiraby, C | 1 |
| Humphreys, SM | 2 |
| Frayn, KN | 5 |
| Vidal, H | 3 |
| Karpe, F | 2 |
| Rabasa-Lhoret, R | 1 |
| Bastard, JP | 1 |
| Jan, V | 1 |
| Ducluzeau, PH | 1 |
| Andreelli, F | 1 |
| Guebre, F | 1 |
| Bruzeau, J | 1 |
| Louche-Pellissier, C | 1 |
| MaItrepierre, C | 1 |
| Peyrat, J | 1 |
| Chagné, J | 1 |
| Laville, M | 1 |
| Tordjman, J | 1 |
| Khazen, W | 1 |
| Antoine, B | 1 |
| Chauvet, G | 1 |
| Quette, J | 1 |
| Fouque, F | 3 |
| Beale, EG | 2 |
| Benelli, C | 3 |
| Forest, C | 3 |
| Petersen, KF | 2 |
| Dufour, S | 2 |
| Befroy, D | 2 |
| Garcia, R | 1 |
| Shulman, GI | 3 |
| Robinson, AC | 1 |
| Jeffs, JA | 1 |
| Gray, RG | 1 |
| Bannister, PA | 1 |
| Mather, H | 2 |
| Gallagher, JJ | 1 |
| Robinson, S | 3 |
| Nattrass, M | 4 |
| Venkatesan, S | 2 |
| Halliday, D | 1 |
| Johnston, DG | 6 |
| Hong, SE | 1 |
| Ahn, IS | 1 |
| Jung, HS | 1 |
| Rayner, DV | 1 |
| Do, MS | 1 |
| Petersen, EW | 1 |
| Carey, AL | 1 |
| Sacchetti, M | 1 |
| Steinberg, GR | 1 |
| Macaulay, SL | 1 |
| Febbraio, MA | 1 |
| Merritt, ME | 1 |
| Sherry, AD | 1 |
| Ravikumar, B | 1 |
| Carey, PE | 1 |
| Snaar, JE | 1 |
| Deelchand, DK | 1 |
| Cook, DB | 1 |
| Neely, RD | 1 |
| English, PT | 1 |
| Firbank, MJ | 1 |
| Morris, PG | 1 |
| Taylor, R | 3 |
| St-Pierre, J | 2 |
| Vohl, MC | 2 |
| Després, JP | 2 |
| Gaudet, D | 2 |
| Adiels, M | 1 |
| Borén, J | 1 |
| Caslake, MJ | 1 |
| Stewart, P | 1 |
| Soro, A | 1 |
| Westerbacka, J | 1 |
| Wennberg, B | 1 |
| Olofsson, SO | 1 |
| Packard, C | 1 |
| Taskinen, MR | 5 |
| Carpentier, AC | 2 |
| Frisch, F | 2 |
| Cyr, D | 2 |
| Généreux, P | 1 |
| Giguère, R | 1 |
| Baillargeon, JP | 2 |
| Rajamand, N | 1 |
| Woerle, HJ | 1 |
| Szoke, E | 1 |
| Meyer, C | 2 |
| Dostou, JM | 1 |
| Wittlin, SD | 1 |
| Gosmanov, NR | 1 |
| Welle, SL | 1 |
| Gerich, JE | 1 |
| Eid, A | 1 |
| Bodin, S | 1 |
| Ferrier, B | 1 |
| Delage, H | 1 |
| Boghossian, M | 1 |
| Martin, M | 1 |
| Baverel, G | 1 |
| Conjard, A | 1 |
| Boschmann, M | 1 |
| Kreuzberg, U | 1 |
| Engeli, S | 1 |
| Adams, F | 1 |
| Franke, G | 1 |
| Klaua, S | 1 |
| Scholze, J | 1 |
| Weidinger, G | 1 |
| Luft, FC | 1 |
| Sharma, AM | 1 |
| Jordan, J | 1 |
| Kishore, P | 1 |
| Tonelli, J | 1 |
| Koppaka, S | 1 |
| Fratila, C | 1 |
| Bose, A | 1 |
| Lee, DE | 1 |
| Reddy, K | 2 |
| Hawkins, M | 2 |
| Forbes, S | 1 |
| Dungu, J | 1 |
| Anyaoku, V | 2 |
| Bannister, P | 1 |
| Forster, D | 1 |
| Dissanayake, S | 1 |
| McCarthy, MI | 1 |
| MacDonald, IA | 1 |
| Boon, H | 1 |
| Blaak, EE | 2 |
| Saris, WH | 2 |
| Keizer, HA | 1 |
| Wagenmakers, AJ | 1 |
| van Loon, LJ | 1 |
| Cadoudal, T | 2 |
| Blouin, JM | 1 |
| Collinet, M | 1 |
| Loizon, E | 1 |
| Lavoie, F | 1 |
| Bourbonnais, A | 1 |
| Cunnane, SC | 1 |
| Drouin, R | 1 |
| Kalhan, SC | 1 |
| Bugianesi, E | 1 |
| McCullough, AJ | 1 |
| Hanson, RW | 1 |
| Kelley, DE | 1 |
| Ferlito, S | 1 |
| Del Campo, F | 1 |
| Indelicato, G | 1 |
| Di Vincenzo, S | 1 |
| Fichera, C | 1 |
| La Vignera, A | 1 |
| Rupp, WM | 1 |
| Rohde, TD | 1 |
| Wigness, BD | 1 |
| Blackshear, PJ | 2 |
| Buchwald, H | 1 |
| Cignarelli, M | 1 |
| Blonda, M | 1 |
| Cospite, MR | 1 |
| Damato, A | 1 |
| Nardelli, G | 1 |
| Giorgino, R | 1 |
| Smith, U | 2 |
| Lönnroth, P | 3 |
| Cummings, MH | 1 |
| Watts, GF | 1 |
| Umpleby, AM | 1 |
| Hennessy, TR | 1 |
| Naoumova, R | 1 |
| Slavin, BM | 1 |
| Thompson, GR | 1 |
| Sönksen, PH | 1 |
| Gelding, SV | 2 |
| Coldham, N | 1 |
| Niththyananthan, R | 2 |
| Hughes, SJ | 1 |
| Suzuki, K | 1 |
| Goto, Y | 1 |
| Puhakainen, I | 3 |
| Ahola, I | 1 |
| Yki-Järvinen, H | 5 |
| Blackman, JD | 1 |
| Senseng, D | 1 |
| Quinn, L | 1 |
| Mazzone, T | 1 |
| Tu, KY | 1 |
| Matthews, R | 1 |
| Topek, NH | 1 |
| Matthews, KS | 1 |
| Jeng, CY | 1 |
| Sheu, WH | 1 |
| Jaspan, JB | 2 |
| Polonsky, KS | 1 |
| Chen, YD | 2 |
| Reaven, GM | 2 |
| Sener, A | 1 |
| Malaisse-Lagae, F | 1 |
| Ostenson, CG | 1 |
| Malaisse, WJ | 3 |
| Chan, SP | 1 |
| Skinner, E | 1 |
| Gray, IP | 2 |
| Saloranta, C | 2 |
| Groop, L | 2 |
| Ekstrand, A | 1 |
| Franssila-Kallunki, A | 1 |
| Singh, BM | 1 |
| Krentz, AJ | 2 |
| Stolba, P | 1 |
| Kvapil, M | 1 |
| Wichterle, D | 1 |
| Dvorák, P | 1 |
| Widen, E | 1 |
| Härkönen, M | 1 |
| Melander, A | 1 |
| Berrish, TS | 1 |
| Elliott, C | 1 |
| Cooper, BG | 1 |
| Reed, JW | 1 |
| Orskov, H | 2 |
| Alberti, KG | 7 |
| Walker, M | 4 |
| Vuorinen-Markkola, H | 1 |
| Baynes, C | 2 |
| Elkeles, RS | 2 |
| Henderson, AD | 2 |
| Richmond, W | 2 |
| Piatti, PM | 3 |
| Monti, L | 1 |
| Brown, M | 1 |
| Hetherington, C | 1 |
| Antsiferov, M | 1 |
| Sobey, W | 1 |
| Hales, CN | 1 |
| Fulcher, GR | 3 |
| Farrer, M | 2 |
| Johnson, AS | 1 |
| Akanji, AO | 3 |
| Osifo, E | 1 |
| Kirk, M | 1 |
| Hockaday, TD | 3 |
| Gudbjörnsdóttir, HS | 1 |
| Andersson, OK | 1 |
| Lönnroth, PN | 2 |
| Monti, LD | 1 |
| Conti, M | 1 |
| Brown, MD | 1 |
| Pozza, G | 2 |
| Andrikopoulos, S | 1 |
| Proietto, J | 1 |
| Pontiroli, AE | 1 |
| Pacchioni, M | 1 |
| Cassisa, C | 1 |
| Camisasca, R | 1 |
| Hellström, L | 1 |
| Reynisdottir, S | 1 |
| Dauzats, M | 1 |
| Tappy, L | 1 |
| Tounian, P | 1 |
| Paquot, N | 1 |
| Axelsen, M | 1 |
| Arvidsson Lenner, R | 1 |
| Miyashita, Y | 1 |
| Hashiguchi, S | 1 |
| Totuka, M | 1 |
| Itoh, Y | 1 |
| Watanabe, J | 1 |
| Shirai, K | 1 |
| Irie, M | 1 |
| Larsen, JJ | 2 |
| Dela, F | 2 |
| Kjaer, M | 1 |
| Galbo, H | 2 |
| Shelgikar, KM | 1 |
| Naik, SS | 1 |
| Khopkar, M | 1 |
| Bhat, DS | 1 |
| Raut, KN | 1 |
| Joglekar, CV | 1 |
| Gerard, ME | 1 |
| Yajnik, CS | 1 |
| Stumvoll, M | 1 |
| Nadkarni, V | 1 |
| Dostou, J | 1 |
| Mitrakou, A | 1 |
| Gerich, J | 2 |
| Ladriere, L | 2 |
| Verbruggen, I | 1 |
| Grue-Sørensen, G | 1 |
| Björkling, F | 2 |
| Willem, R | 1 |
| Boden, G | 2 |
| Sandhu, H | 1 |
| Wiesenthal, SR | 1 |
| MacDonald, PE | 1 |
| McCall, RH | 1 |
| Tchipashvili, V | 1 |
| Rashid, S | 1 |
| Satkunarajah, M | 1 |
| Irwin, DM | 1 |
| Shi, ZQ | 1 |
| Brubaker, PL | 1 |
| Wheeler, MB | 1 |
| Vranic, M | 1 |
| Efendic, S | 1 |
| Giacca, A | 1 |
| Svedman, C | 1 |
| Samra, JS | 1 |
| Clark, ML | 1 |
| Levy, JC | 1 |
| Kemerink, GJ | 1 |
| Pakbiers, MT | 1 |
| Wolffenbuttel, BH | 1 |
| Heidendal, GA | 1 |
| Madsbad, S | 1 |
| Rave, K | 1 |
| Heise, T | 1 |
| Clausson, P | 1 |
| Hirschberger, S | 1 |
| Heinemann, L | 1 |
| Getty, L | 1 |
| Panteleon, AE | 1 |
| Mittelman, SD | 1 |
| Dea, MK | 1 |
| Bergman, RN | 1 |
| Christiansen, MP | 1 |
| Linfoot, PA | 1 |
| Neese, RA | 1 |
| Hellerstein, MK | 1 |
| Webber, J | 1 |
| Whitelaw, D | 1 |
| Smith, JM | 1 |
| Brisson, D | 1 |
| Perron, P | 1 |
| Hudson, TJ | 1 |
| Capulong, E | 1 |
| Mozzoli, M | 1 |
| Arnqvist, H | 1 |
| Håkanson, E | 2 |
| Jorfeldt, L | 2 |
| Svedjeholm, R | 2 |
| Hemmerling, TM | 1 |
| Schmidt, J | 1 |
| Kern, S | 1 |
| Jacobi, KE | 1 |
| van der Merwe, MT | 1 |
| Schlaphoff, GP | 1 |
| Crowther, NJ | 1 |
| Boyd, IH | 1 |
| Joffe, BI | 1 |
| Moore, MC | 1 |
| Mann, SL | 1 |
| Cherrington, AD | 1 |
| Mayerson, AB | 1 |
| Hundal, RS | 1 |
| Lebon, V | 1 |
| Cline, GW | 1 |
| Enocksson, S | 1 |
| Inzucchi, SE | 1 |
| Sjöstrand, M | 1 |
| Gudbjörnsdottir, S | 1 |
| Holmäng, A | 1 |
| Ekberg, K | 1 |
| Caprio, S | 1 |
| Gabriely, I | 1 |
| Wozniak, R | 1 |
| Rossetti, L | 1 |
| Shamoon, H | 1 |
| Catalano, C | 2 |
| Agius, L | 1 |
| Ellis, SH | 1 |
| Hardman, M | 1 |
| Koivisto, VA | 2 |
| Skowronski, R | 1 |
| Hollenbeck, CB | 1 |
| Varasteh, BB | 1 |
| Nurjhan, N | 1 |
| Consoli, A | 1 |
| Johnson, AB | 1 |
| Argyraki, M | 1 |
| Thow, JC | 1 |
| Jones, IR | 1 |
| Broughton, D | 1 |
| Miller, M | 1 |
| Hughes, CL | 1 |
| Marchetti, P | 1 |
| Gregorio, F | 1 |
| Benzi, L | 1 |
| Giannarelli, R | 1 |
| Cecchetti, P | 1 |
| Villani, G | 1 |
| Di Cianni, G | 1 |
| Di Carlo, A | 1 |
| Brunetti, P | 1 |
| Navalesi, R | 1 |
| Coppack, SW | 1 |
| Doll, HA | 1 |
| Pim, B | 1 |
| Humphreys, S | 1 |
| Thursfield, V | 1 |
| Bruce, MA | 1 |
| Sane, T | 1 |
| Helve, E | 1 |
| Karonen, SL | 1 |
| Nikkilä, EA | 1 |
| Thorburn, AW | 1 |
| Crapo, PA | 1 |
| Beltz, WF | 1 |
| Wallace, P | 1 |
| Witztum, JL | 1 |
| Henry, RR | 1 |
| Uccella, R | 1 |
| Hagander, B | 1 |
| Björck, I | 1 |
| Asp, NG | 1 |
| Lundquist, I | 1 |
| Nilsson-Ehle, P | 1 |
| Schrezenmeir, J | 1 |
| Scherstén, B | 1 |
| Samad, AH | 1 |
| Ty Willing, TS | 1 |
| Bolinder, J | 1 |
| Leslie, P | 1 |
| Jung, RT | 1 |
| Isles, TE | 1 |
| Baty, J | 1 |
| Zawadzki, JK | 1 |
| Wolfe, RR | 1 |
| Mott, DM | 1 |
| Lillioja, S | 1 |
| Howard, BV | 1 |
| Bogardus, C | 1 |
| Jackson, RA | 1 |
| Hawa, MI | 1 |
| Sim, BM | 1 |
| Disilvio, L | 1 |
| Featherbe, D | 1 |
| Kurtz, AB | 1 |
| Roussell, AM | 1 |
| Nathan, DM | 1 |
| Minaker, KL | 1 |
| Rowe, JW | 1 |
| Robbins, DC | 1 |
| Cohen, AM | 1 |
| Bhattacharjee, K | 3 |
| Pramanik, S | 3 |
| Chowdhury, SD | 3 |
| Basu, BR | 2 |
| Mondal, LK | 3 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus[NCT01032629] | Phase 3 | 4,330 participants (Actual) | Interventional | 2009-12-09 | Completed | ||
| Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging[NCT02833415] | Phase 4 | 40 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors[NCT02792400] | 24 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| Mechanistic Studies in Human Subcutaneous Adipose Tissue[NCT06065930] | 45 participants (Anticipated) | Observational | 2023-05-05 | Recruiting | |||
| A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.[NCT01147861] | Phase 1 | 39 participants (Actual) | Interventional | 2010-07-01 | Completed | ||
| A Dietary Intervention With Functional Foods Reduce Metabolic Endotoxemia and Attenuates Biochemical Abnormalities in Subjects With Type 2 Diabetes by Modifying the Gut Microbiota.[NCT03421301] | 81 participants (Actual) | Interventional | 2014-08-07 | Completed | |||
| A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus[NCT04432090] | Phase 2 | 67 participants (Actual) | Interventional | 2021-04-21 | Active, not recruiting | ||
| Recombinant Human Leptin Therapy Effects on Insulin Action[NCT01207934] | 18 participants (Actual) | Interventional | 1998-08-31 | Completed | |||
| An Exploratory Study to Evaluate the Effects of Roflumilast on Insulin Sensitivity and Metabolic Parameters in Prediabetic Overweight and Obese Individuals[NCT01862029] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2013-05-22 | Completed | ||
| Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6[NCT04687540] | 25 participants (Actual) | Interventional | 2021-04-09 | Completed | |||
| Regulation of Lipolysis by Insulin in Skeletal Muscle and Adipose Tissue in Type 2 Diabetes[NCT01680133] | 20 participants (Actual) | Observational | 2007-06-30 | Completed | |||
| A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.[NCT04271189] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| Prospective Randomized Trial of Polymem vs. Bacitracin/Xeroform for Superficial Second Degree Burns[NCT00479193] | Phase 1 | 0 participants (Actual) | Interventional | 2006-10-31 | Withdrawn | ||
| Dried Fruit as a Means for Lowering the Glycemic Response to High Glycemic Index-carbohydrate Foods[NCT02960373] | 10 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | |||
| An Acute Randomized Dose-finding Equivalence Trial of Small, Catalytic Doses of Fructose and Allulose on Postprandial Carbohydrate Metabolism: The Fructose and Allulose Catalytic Effects (FACE) Study[NCT02459834] | 50 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study[NCT02796950] | 8 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| A Randomized Trial Evaluating the Effects of One-Year Caloric Restriction and 12-Week Exercise Training Intervention in Obese Adults With Type 2 Diabetes: Emphasis on Metabolic Control and Resting Metabolic Rate[NCT03785379] | 23 participants (Actual) | Interventional | 2013-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in Estimated Glomerular Filtration Rate (eGFR) was assessed at end of treatment. GFR is a measure of the rate at which blood is filtered by the kidney. Modification of Diet in Renal Disease (MDRD) is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and sex. eGFR milliliters/minute/1.73 meters square (mL/min/1.73 m^2) = 175 * (serum creatinine) ^ 1.154 * (Age) ^-0.203 *(0.742 if female) * (1.21 if Black). (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Placebo | -5.23 |
| Canagliflozin 100 mg | -3.55 |
| Canagliflozin 300 mg | -3.98 |
Change from baseline in the fasting plasma glucose levels at end-of-treatment was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Millimoles per liter (mmol/L) (Least Squares Mean) |
|---|---|
| Placebo | 0.16 |
| Canagliflozin 100 mg | -0.42 |
| Canagliflozin 300 mg | -0.57 |
Change from baseline in glycated hemoglobin (HbA1c) percentage (%) was assessed at end of treatment. Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average glucose concentration in the blood. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | HbA1c (%) (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Canagliflozin 100 mg | -0.26 |
| Canagliflozin 300 mg | -0.31 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100 percent. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Percentage of HOMA2 (Least Squares Mean) |
|---|---|
| Placebo | 4.02 |
| Canagliflozin 100 mg | 6.82 |
| Canagliflozin 300 mg | 8.09 |
Change from baseline in LDL-C to HDL-C ratio was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.04 |
| Canagliflozin 100 mg | -0.02 |
| Canagliflozin 300 mg | 0.00 |
A raised proinsulin-to-insulin ratio due to impaired processing of proinsulin is an early marker of beta cell dysfunction. Beta-cell dysfunction was evaluated by calculating the PI/I ratio, which estimates the capacity of beta cells to convert proinsulin to insulin and may represent an acceptable method to indicate the degree of beta-cell secretion. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Picomole per milli international units (Least Squares Mean) |
|---|---|
| Placebo | 0.70 |
| Canagliflozin 100 mg | 0.67 |
| Canagliflozin 300 mg | 1.03 |
Change from baseline in triglycerides levels was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 0.05 |
| Canagliflozin 100 mg | 0.13 |
| Canagliflozin 300 mg | 0.09 |
Urinary Albumin/Creatinine Ratio is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine. (NCT01032629)
Timeframe: Baseline and End of treatment (approximately 338 weeks)
| Intervention | Milligram per gram (mg/g) (Geometric Mean) |
|---|---|
| Placebo | 29.30 |
| Canagliflozin 100 mg | 25.50 |
| Canagliflozin 300 mg | 24.47 |
MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented. (NCT01032629)
Timeframe: Up to approximately 8 years
| Intervention | Events per 1000 patient-year (Number) |
|---|---|
| Placebo | 30.36 |
| Canagliflozin 100 mg | 28.41 |
| Canagliflozin 300 mg | 25.37 |
| Canagliflozin (Total) | 26.89 |
Percent change from baseline in body weight was assessed at the end of treatment. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.50 |
| Canagliflozin 100 mg | -3.47 |
| Canagliflozin 300 mg | -4.12 |
Progression defined as the development of micro-albuminuria (albumin/creatinine ratio (ACR) greater than or equal to [>=] 30 milligram per gram (mg/g) and less than or equal to <= 300 mg/g) or macroalbuminuria (ACR of >300 mg/g) in a participant with baseline normoalbuminuria or the development of macro-albuminuria in a participant with baseline microalbuminuria. Percentage of participants with progression of albuminuria at the end-of-treatment were assessed. (NCT01032629)
Timeframe: End of treatment (approximately 338 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 24.0 |
| Canagliflozin 100 mg | 20.2 |
| Canagliflozin 300 mg | 18.3 |
Change from baseline in cholesterol, high-density lipoprotein cholesterol and low density lipoprotein cholesterol levels were assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mmol/L (Least Squares Mean) | ||
|---|---|---|---|
| Cholesterol (change at EOT) | HDL-C (change at EOT) | LDL-C (change at EOT) | |
| Canagliflozin 100 mg | 0.11 | 0.04 | 0.04 |
| Canagliflozin 300 mg | 0.16 | 0.05 | 0.10 |
| Placebo | -0.07 | -0.01 | -0.07 |
Change from baseline in systolic blood pressure and diastolic blood pressure was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Millimeter of mercury (mmHg) (Least Squares Mean) | |
|---|---|---|
| SBP(Change at end of treatment) | DBP (Change at end of treatment) | |
| Canagliflozin 100 mg | -4.91 | -3.70 |
| Canagliflozin 300 mg | -6.49 | -4.51 |
| Placebo | -1.96 | -2.88 |
[U-13C3] glycerol enrichment in plasma blood glucose over time will be measured by nuclear magnetic resonance spectroscopy. This is a percentage change from baseline to follow up in the percent enrichment of exogenous glycerol in blood glucose. We are unable to report a measure of central tendency and dispersion as the outcome is a percent change in the area under the enrichment curve for each group between baseline and follow-up. There is no measure of central tendency for these measurements without bootstrapping, which was not performed. (NCT02833415)
Timeframe: 3 months
| Intervention | Percentage change (Number) |
|---|---|
| Empagliflozin | 6.5 |
| Placebo | 1.4 |
pre-treatment glucose disposal. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight. (NCT01207934)
Timeframe: baseline
| Intervention | mmol/kg body weight/minute (Mean) |
|---|---|
| Placebo | 14.3 |
| Low Dose Leptin | 18.4 |
| High Dose Leptin | 16.7 |
Leptin is an endogenous hormone. Here we measure the pre-treatment concentration of naturally-occurring leptin in the blood. (NCT01207934)
Timeframe: baseline
| Intervention | Micrograms/Liter (Mean) |
|---|---|
| Placebo | 27 |
| Low Dose Leptin | 24 |
| High Dose Leptin | 35 |
This is a measure of the body's ability to metabolize sugar after treatment with either leptin or a placebo. We compare the effect of leptin therapy on insulin-mediated stimulation of glucose disposal with that of placebo. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight. (NCT01207934)
Timeframe: fourteen days
| Intervention | mmol/kg body weight/minute (Mean) |
|---|---|
| Placebo | 17.5 |
| Low Dose Leptin | 20.7 |
| High Dose Leptin | 19.1 |
plasma leptin levels after fourteen days ingestion of either leptin or placebo. (NCT01207934)
Timeframe: fourteen days
| Intervention | Micrograms/Liter (Mean) |
|---|---|
| Placebo | 25 |
| Low Dose Leptin | 76 |
| High Dose Leptin | 5024 |
Our primary outcome measure is the change in peripheral insulin sensitivity. The hyperinsulinemic euglycemic clamp procedure's M value, which was obtained post-roflumilast, was used for this primary outcome assessment. (NCT01862029)
Timeframe: 6 weeks
| Intervention | mg/grams Fat Free Mass/minute (Mean) |
|---|---|
| Post-roflumilast | 70 |
Our primary outcome measure is the change in peripheral insulin sensitivity. The hyperinsulinemic euglycemic clamp procedure's M value, which was obtained before the subjects began roflumilast, was used to assess the primary outcome. (NCT01862029)
Timeframe: Baseline
| Intervention | mg/grams Fat Free Mass/minute (Mean) |
|---|---|
| Pre-roflumilast | 48.7 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
8 reviews available for glycerol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Mammalian aquaglyceroporin function in metabolism.
Topics: Adipose Tissue; Animals; Aquaglyceroporins; Biological Transport, Active; Diabetes Mellitus, Type 2; | 2016 |
Regulation of glyceroneogenesis and phosphoenolpyruvate carboxykinase by fatty acids, retinoic acids and thiazolidinediones: potential relevance to type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids; Gene Expression Regulation, Enzymologic; Glycerol; | 2003 |
Genetic aspects of diabetes and its cardiovascular complications: contribution of genetics to risk assessment and clinical management.
Topics: Albuminuria; Coronary Artery Disease; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; | 2005 |
[Glyceroneogenesis and PEPCK-C: pharmacological targets in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids; Glycerol; Humans; Insulin; Insulin Resist | 2008 |
Autoregulation of endogenous glucose production in man.
Topics: Amino Acids; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fructose; Gluconeogenesis; Glycerol; Glyc | 1997 |
Insulin resistance in childhood obesity.
Topics: Abdomen; Adipose Tissue; Adolescent; Body Composition; Cardiovascular Diseases; Child; Diabetes Mell | 2002 |
Effect of acetate infusion on energy expenditure and substrate oxidation rates in non-diabetic and diabetic subjects.
Topics: Acetates; Adult; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Glycerol; | 1989 |
45 trials available for glycerol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
Topics: 3-Hydroxybutyric Acid; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; G | 2022 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.
Topics: Adipose Tissue; Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind | 2020 |
Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes.
Topics: Aged; Area Under Curve; Diabetes Mellitus, Type 2; Dietary Fats, Unsaturated; Female; Gastric Inhibi | 2018 |
GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Adm | 2013 |
Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Metabolism | 2014 |
Decreased lipases and fatty acid and glycerol transporter could explain reduced fat in diabetic morbidly obese.
Topics: Adiposity; Adult; Aquaporins; Biological Transport; CD36 Antigens; Diabetes Mellitus, Type 2; Down-R | 2014 |
Use of a urea, arginine and carnosine cream versus a standard emollient glycerol cream for treatment of severe xerosis of the feet in patients with type 2 diabetes: a randomized, 8 month, assessor-blinded, controlled trial.
Topics: Administration, Cutaneous; Aged; Arginine; Carnosine; Diabetes Mellitus, Type 2; Emollients; Female; | 2015 |
The effects of interval- vs. continuous exercise on excess post-exercise oxygen consumption and substrate oxidation rates in subjects with type 2 diabetes.
Topics: Body Mass Index; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Eating; Energy Metabolism; Exerci | 2016 |
Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glycero | 2009 |
The effects of peroral glycerol on plasma osmolarity in diabetic patients and healthy individuals.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Diabetes Mellit | 2009 |
The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Atenolol; Complement C3; Cross-Over Studies; Diabetes | 2012 |
Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glycero | 2011 |
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Aminopyridines; Area Under Curve; Benzamides; Blood Glucose; Body Weight; C-Peptide; Cy | 2012 |
An urea, arginine and carnosine based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the treatment of severe xerosis of the feet in Type 2 diabetic patients in comparison with glycerol-based emollient cream. A randomized, assessor-blinded, controll
Topics: Administration, Topical; Adult; Aged; Arginine; Carnosine; Diabetes Mellitus, Type 2; Diabetic Foot; | 2012 |
A "futile cycle" induced by thiazolidinediones in human adipose tissue?
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Carrier Proteins; Cells, Cultured; Diabetes Mell | 2003 |
Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterifi | 2003 |
Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes.
Topics: Apolipoprotein B-100; Apolipoproteins B; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fatty A | 2004 |
Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro.
Topics: 3T3-L1 Cells; Aged; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; G | 2005 |
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia.
Topics: Adult; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, VLDL; Deuterium; Diabetes Me | 2005 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blo | 2006 |
Time-dependent effects of free fatty acids on glucose effectiveness in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluco | 2006 |
Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind M | 2008 |
Microdialysis technique as a monitoring system for acute complications of diabetes.
Topics: Abdominal Fat; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2008 |
Dietary supplementation with n-3 fatty acids increases gluconeogenesis from glycerol but not hepatic glucose production in patients with non-insulin-dependent diabetes mellitus.
Topics: Calorimetry, Indirect; Cholesterol Esters; Corn Oil; Cross-Over Studies; Diabetes Mellitus, Type 2; | 1995 |
Clinical evaluation of a semipermeable polymeric membrane dressing for the treatment of chronic diabetic foot ulcers.
Topics: Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Foot; Female; Glycer | 1994 |
Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
Topics: Blood Glucose; Calorimetry; Chromatography, High Pressure Liquid; Circadian Rhythm; Diabetes Mellitu | 1993 |
The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; C-Peptide; Calorimetry; Carbon Dioxide; Diabetes Mellitus, Typ | 1993 |
Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Fatty | 1993 |
The effects of subcutaneous human proinsulin on the production of 64/65 split proinsulin, glucose turnover and intermediary metabolism in non-insulin-dependent diabetic man.
Topics: Alanine; Blood Glucose; Deuterium; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose Cl | 1993 |
Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Topics: Adult; Alanine; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterifie | 1993 |
The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type | 1993 |
Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Forearm | 1996 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
Suppression of the nocturnal free fatty acid levels by bedtime cornstarch in NIDDM subjects.
Topics: Administration, Oral; Aged; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Adminis | 1997 |
Lack of effects of the beta3-adrenoreceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in Type 2 diabetic patients.
Topics: Adrenergic beta-Agonists; Adult; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Double- | 1999 |
Effects of high-dose glucose-insulin-potassium on myocardial metabolism after coronary surgery in patients with Type II diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Analysis of Variance; Angina Pectoris; Cardiopulmonary Bypass; Catheter | 2001 |
Comparison of a continuous glucose-insulin-potassium infusion versus intermittent bolus application of insulin on perioperative glucose control and hormone status in insulin-treated type 2 diabetics.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, | 2001 |
Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes.
Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, N | 2001 |
Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes.
Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, N | 2001 |
Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes.
Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, N | 2001 |
Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes.
Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, N | 2001 |
Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesteri | 1992 |
Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Ty | 1992 |
Metabolic effects of aldose reductase inhibition in diabetic man.
Topics: Alanine; Aldehyde Reductase; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Di | 1992 |
Effect of acetate infusion on energy expenditure and substrate oxidation rates in non-diabetic and diabetic subjects.
Topics: Acetates; Adult; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Glycerol; | 1989 |
Hormonal and metabolic responses to breakfast meals in niddm: comparison of white and whole-grain wheat bread and corresponding extruded products.
Topics: Adult; Aged; Blood Glucose; Bread; C-Peptide; Diabetes Mellitus, Type 2; Dietary Fiber; Female; Gast | 1985 |
Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Topics: 1-Deoxynojirimycin; 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Clinical Trials as Topic; Diabete | 1988 |
110 other studies available for glycerol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect and mechanism of glycerol monostearate dimer (GMS-D) and baking-treatment on the structure, in vitro digestion of gelatinized potato starch-GMS-D.
Topics: Amylose; Diabetes Mellitus, Type 2; Digestion; Glycerol; Humans; Quality of Life; Solanum tuberosum; | 2022 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
Expression and characterisation of human glycerol kinase: the role of solubilising agents and molecular chaperones.
Topics: Diabetes Mellitus, Type 2; Escherichia coli; Glycerol; Glycerol Kinase; Humans; Molecular Chaperones | 2023 |
Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4
Topics: Adipose Tissue; Adipose Tissue, White; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Chemokin | 2023 |
Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glycerol; Humans; Insulin; Insulin Resistance | 2023 |
Glycerol contributes to tuberculosis susceptibility in male mice with type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Glycerol; Humans; Male; Mice; Mycobacterium tuberculosis; Strept | 2023 |
The metabolic implications of aquaporin 7 (AQP7) promoter variants in lean children and children with obesity.
Topics: Adolescent; Aquaporins; Child; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; | 2020 |
Acute Kidney Injury with Hemolysis after Glycerin Enema-induced Rectal Injury in a Patient with Type 2 Diabetes.
Topics: Acute Kidney Injury; Aged; Colonoscopy; Diabetes Mellitus, Type 2; Enema; Glycerol; Hematologic Test | 2020 |
Metabolic and Non-metabolic Roles of Pyruvate Kinase M2 Isoform in Diabetic Retinopathy.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 6; Diabetes Mellitus, Type 2; Diabetic Retinopat | 2020 |
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Topics: Benzhydryl Compounds; Biphenyl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug | 2020 |
Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study.
Topics: Adipose Tissue; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonest | 2021 |
Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates.
Topics: Animals; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diabetes Melli | 2021 |
The kinetics of islet amyloid polypeptide phase-separated system and hydrogel formation are critically influenced by macromolecular crowding.
Topics: Alzheimer Disease; Amyloid; Amyloidogenic Proteins; Dextrans; Diabetes Mellitus, Type 2; Ficoll; Gly | 2021 |
Sympathetic nervous system activity and anti-lipolytic response to iv-glucose load in subcutaneous adipose tissue of obese and obese type 2 diabetic subjects.
Topics: Adrenergic Agonists; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycerol; Hum | 2017 |
Performance of individually measured vs population-based C-peptide kinetics to assess β-cell function in the presence and absence of acute insulin resistance.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Glycerol; Hormones; H | 2018 |
Association of genetic variants in RETN, NAMPT and ADIPOQ gene with glycemic, metabolic traits and diabetes risk in a Chinese population.
Topics: Adiponectin; Aged; Alanine Transaminase; Asian People; Aspartate Aminotransferases; China; Creatinin | 2018 |
Pro-inflammatory cytokine-induced lipolysis after an episode of acute pancreatitis.
Topics: Acute Disease; Adult; Aged; Biomarkers; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, | 2018 |
Peritoneal and Systemic Responses of Obese Type II Diabetic Rats to Chronic Exposure to a Hyperbranched Polyglycerol-Based Dialysis Solution.
Topics: Animals; Biomarkers; Cytokines; Diabetes Mellitus, Type 2; Dialysis Solutions; Disease Models, Anima | 2018 |
Effects of transaldolase exchange on estimates of gluconeogenesis in type 2 diabetes.
Topics: Acetic Acid; Aged; Carbon Radioisotopes; Deuterium Oxide; Diabetes Mellitus, Type 2; Fasting; Female | 2013 |
Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men.
Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Monounsaturated; | 2013 |
Microdialysis monitoring of glucose, lactate, glycerol, and pyruvate in patients with diabetic ketoacidosis.
Topics: Adipose Tissue; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus | 2013 |
Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Flow Cytometry; Gluco | 2014 |
Primary defects in lipolysis and insulin action in skeletal muscle cells from type 2 diabetic individuals.
Topics: Biological Transport; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Diglycerides; Female; Gene Ex | 2015 |
Fatty Acids, Obesity and Insulin Resistance.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Glycerol; Humans; | 2015 |
The Role of PDE3B Phosphorylation in the Inhibition of Lipolysis by Insulin.
Topics: 3T3-L1 Cells; Adipocytes, Brown; Animals; Cells, Cultured; Cyclic AMP; Cyclic Nucleotide Phosphodies | 2015 |
Modeling changes in glucose and glycerol rates of appearance when true basal rates of appearance cannot be readily determined.
Topics: Adolescent; Algorithms; Blood Glucose; Case-Control Studies; Child; Deuterium; Diabetes Mellitus, Ty | 2016 |
Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS.
Topics: Amino Acids, Branched-Chain; Asian People; Blood Glucose; Case-Control Studies; Chromatography, Liqu | 2016 |
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fa | 2008 |
Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes.
Topics: Autonomic Nervous System; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty | 2009 |
Human mesenteric adipose tissue plays unique role versus subcutaneous and omental fat in obesity related diabetes.
Topics: Adiponectin; CD36 Antigens; Diabetes Mellitus, Type 2; Fatty Acids; Gene Expression Regulation; Glyc | 2008 |
The impact of obesity, sex, and diet on hepatic glucose production in cats.
Topics: Animals; Blood Glucose; Body Mass Index; Body Weight; Carbon Isotopes; Cats; Citrate (si)-Synthase; | 2009 |
Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21.
Topics: Cell Line; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Fibroblast Growth | 2009 |
Intraoperative muscle and fat metabolism in diabetic patients during coronary artery bypass grafting surgery: a parallel microdialysis and organ balance study.
Topics: Aged; Anesthesia, General; Blood Glucose; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Feasibi | 2009 |
Analyte flux at a biomaterial-tissue interface over time: implications for sensors for type 1 and 2 diabetes mellitus.
Topics: Adult; Aged; Biocompatible Materials; Biopsy; Biosensing Techniques; Diabetes Mellitus, Type 1; Diab | 2010 |
Short term voluntary overfeeding disrupts brain insulin control of adipose tissue lipolysis.
Topics: Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Dietary Fats; Energy Intake; Glucose; Gly | 2012 |
Curcumin attenuates lipolysis stimulated by tumor necrosis factor-α or isoproterenol in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Carrier Proteins; Curcuma; Curcumin; Diabetes Mellitus, Type 2; D | 2012 |
A futile metabolic cycle activated in adipocytes by antidiabetic agents.
Topics: Adipocytes; Animals; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expressi | 2002 |
Reduction of plasma leptin concentrations by arginine but not lipid infusion in humans.
Topics: Adult; Arginine; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fat Emulsions, Int | 2002 |
Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes.
Topics: Adenosine Triphosphate; Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids; Femal | 2004 |
Effect of retinoic acid on leptin, glycerol, and glucose levels in mature rat adipocytes in vitro.
Topics: Adipocytes; Alitretinoin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relations | 2004 |
Differing mechanisms of hepatic glucose overproduction in triiodothyronine-treated rats vs. Zucker diabetic fatty rats by NMR analysis of plasma glucose.
Topics: Animals; Blood Glucose; Citric Acid Cycle; Diabetes Mellitus, Type 2; Glucose; Glycerol; Glycogen; K | 2005 |
Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Area Under Curve; Blood Glucose; Chylomicrons; Diabetes Mellitus, Type 2; Die | 2005 |
On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans.
Topics: Adult; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 2005 |
Subcutaneous microdialysis before and after an oral glucose tolerance test: a method to determine insulin resistance in the subcutaneous adipose tissue in diabetes mellitus.
Topics: Adult; Anthropometry; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 1; | 2005 |
Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes.
Topics: Alanine; Blood Glucose; Carbon Dioxide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Femal | 2006 |
Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructose-Bisphosphatase; Gluconeogenesis | 2006 |
Sustained endogenous glucose production, diminished lipolysis and non-esterified fatty acid appearance and oxidation in non-obese women at high risk of type 2 diabetes.
Topics: Adiposity; Adult; Body Weight; Catecholamines; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, | 2006 |
Substrate source utilisation in long-term diagnosed type 2 diabetes patients at rest, and during exercise and subsequent recovery.
Topics: Biopsy; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Energy Metabolism; Exercise; | 2007 |
Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes.
Topics: Adipose Tissue; Animals; Cytosol; Diabetes Mellitus, Type 2; DNA Primers; Fatty Acids, Nonesterified | 2007 |
Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified | 2008 |
Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gluconeogenesis; Glucose; Gluc | 2008 |
Blood glycerol levels in type-2 diabetics after beta-1-blockade and alpha-2 adrenergic stimulation.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Clonidine; Diabetes Mellitus, T | 1984 |
Clinical experience with insulin-glycerol solution in an implantable pump.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Glycerol; | 1983 |
Alterations of erythrocyte lipid pattern and of some membrane related functions as a consequence of plasma lipid disorder in diabetes mellitus.
Topics: Adult; Apolipoproteins; Apolipoproteins A; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; | 1983 |
Microdialysis assessment of adipose tissue metabolism in post-absorptive obese NIDDM subjects.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Female; Glycerol; Humans; Lactates; Lactic Acid; Male; Mi | 1995 |
Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM.
Topics: Apolipoprotein B-100; Apolipoproteins B; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus | 1995 |
Insulin resistance with respect to lipolysis in non-diabetic relatives of European patients with type 2 diabetes.
Topics: Adult; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Fatty Acids, Nonesterified; Female; G | 1995 |
The role of islet secretory function in the development of diabetes in the GK Wistar rat.
Topics: Aging; Animals; Arginine; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucose; Gl | 1994 |
Glucose and insulin responses in isolated human lymphocytes reflect in vivo status: effects of VLCD treatment.
Topics: Blood Glucose; Body Weight; Cell Division; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Ty | 1994 |
Glucagon does not increase plasma free fatty acid and glycerol concentrations in patients with noninsulin-dependent diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Hu | 1993 |
Metabolism of endogenous nutrients in islets of Goto-Kakizaki (GK) rats.
Topics: Ammonia; Animals; Blood Glucose; Carbon Dioxide; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Gl | 1993 |
Insulin sensitivity in non-diabetic relatives of patients with non-insulin-dependent diabetes from two ethnic groups.
Topics: Adult; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Disease Susceptibility; Europe; Family; Fatty | 1994 |
Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Circadian Rhythm; Diabetes Mellitus, Type 2; Fasting; | 1993 |
Insulin resistance in the regulation of lipolysis and ketone body metabolism in non-insulin dependent diabetes is apparent at very low insulin concentrations.
Topics: Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glycerol | 1993 |
Kinetics of free fatty acids in hypertriglyceridemia. Evidence for different types of insulin resistance.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glycerol; Humans; Hypertriglyceridemia | 1993 |
The effects of glibenclamide on glucose homeostasis and lipoprotein metabolism in poorly controlled type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glyburide; Glycerol; | 1993 |
The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM.
Topics: Adipose Tissue; Analysis of Variance; Blood Glucose; Body Composition; Body Mass Index; Diabetes Mel | 1996 |
The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Alanine; Animals; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Fats; Disea | 1995 |
Adipocyte lipolysis in normal weight subjects with obesity among first-degree relatives.
Topics: Adipocytes; Adrenergic beta-Agonists; Adult; Body Mass Index; Bucladesine; Clonidine; Colforsin; Dia | 1996 |
The effect of growth hormone secreted by mild exercise on fatty acid mobilization in patients with diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Fatty Acids; Fatty Acids, Nonesterified; Female; | 1996 |
The effect of moderate exercise on postprandial glucose homeostasis in NIDDM patients.
Topics: Analysis of Variance; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise; | 1997 |
Circulating lipids and cardiovascular risk in newly diagnosed non-insulin-dependent diabetic subjects in India.
Topics: 3-Hydroxybutyric Acid; Adult; Albuminuria; Angina Pectoris; Cardiovascular Diseases; Cholesterol; Co | 1997 |
Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Arteries; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty | 1998 |
Metabolism of [1,3-(13)C]glycerol-1,2,3-tris(methylsuccinate) and glycerol-1,2,3-tris(methyl[2,3-(13)C]succinate) in hepatocytes from Goto-Kakizaki rats.
Topics: Animals; Carbon Isotopes; Cells, Cultured; Chloride Channels; Diabetes Mellitus, Type 2; Disease Mod | 1999 |
Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty | 1999 |
Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 1999 |
Skin mini-erosion technique for monitoring metabolites in interstitial fluid: its feasibility demonstrated by OGTT results in diabetic and non-diabetic subjects.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Extracellular Space; Female; | 1999 |
Assessment of the nutritional value of glycerol-1,2, 3-tris(methylsuccinate) in fed and starved rats.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Body Weight; Chloride Channels; Diabetes Mellitus, Ty | 1999 |
Microdialysis assessment of local adipose tissue lipolysis during beta-adrenergic stimulation in upper-body-obese subjects with type II diabetes.
Topics: Adipose Tissue; Adrenergic beta-Agonists; Blood Glucose; Diabetes Mellitus, Type 2; Energy Metabolis | 1999 |
The effect of intense exercise on postprandial glucose homeostasis in type II diabetic patients.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Eating; Epinephrine; Exercise; Fatty Acids, Non | 1999 |
Rapid oscillations in omental lipolysis are independent of changing insulin levels in vivo.
Topics: Activity Cycles; Adrenergic beta-Antagonists; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dog | 2000 |
Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Reducing; Energ | 2000 |
Glucose and fatty acid metabolism in type 2 diabetes mellitus: an assessment using low-dose insulin infusion and the hyperinsulinaemic euglycaemic clamp.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Glucose; Glucose | 1999 |
A sequence variation in the mitochondrial glycerol-3-phosphate dehydrogenase gene is associated with increased plasma glycerol and free fatty acid concentrations among French Canadians.
Topics: Adult; Aged; Base Sequence; Canada; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; France; G | 2001 |
Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Gluconeogenesis; Glucose; Gl | 2001 |
Lactate and glycerol release from adipose tissue in lean, obese, and diabetic women from South Africa.
Topics: Adipose Tissue; Adult; Black People; Body Composition; C-Peptide; Diabetes Mellitus; Diabetes Mellit | 2001 |
Myocardial uptake and release of substrates in type II diabetics undergoing coronary surgery.
Topics: 3-Hydroxybutyric Acid; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified | 2001 |
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.
Topics: Adipocytes; Adipose Tissue; Blood Glucose; Body Composition; Calorimetry, Indirect; Diabetes Mellitu | 2002 |
Measurements of interstitial muscle glycerol in normal and insulin-resistant subjects.
Topics: Adult; Diabetes Mellitus, Type 2; Extracellular Space; Fasting; Female; Glucose Clamp Technique; Glu | 2002 |
Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glu | 2002 |
Lipolysis and gluconeogenesis from glycerol are increased in patients with noninsulin-dependent diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluconeogen | 1992 |
Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Glycerol; Hum | 1991 |
Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; | 1992 |
Impaired activation of skeletal muscle glycogen synthase in non-insulin-dependent diabetes mellitus is unrelated to the degree of obesity.
Topics: 3-Hydroxybutyric Acid; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Fe | 1991 |
No reduction in total hepatic glucose output by inhibition of gluconeogenesis with ethanol in NIDDM patients.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Ethanol; Fatty Acids, Nonesterified; Female; Glucone | 1991 |
Do enzymatic analyses of serum triglycerides really need blanking for free glycerol?
Topics: Adipose Tissue; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glycerol; Humans; Triglyceride | 1991 |
Determinants of mild fasting hypertriglyceridaemia in non-insulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, None | 1991 |
Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients.
Topics: Alanine; Blood Glucose; Butyrates; Butyric Acid; Circadian Rhythm; Diabetes Mellitus, Type 2; Glycer | 1990 |
Intravenous glucose tolerance and mortality in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glycerol; | 1990 |
The relationship of plasma acetate with glucose and other blood intermediary metabolites in non-diabetic and diabetic subjects.
Topics: Acetates; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Fatty | 1989 |
Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM.
Topics: Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; F | 1989 |
Lipid metabolism in non-insulin-dependent diabetes: effects of long-term treatment with fructose-supplemented mixed meals.
Topics: Blood Glucose; Cholesterol; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Energy Intake; Fatty Acids | 1989 |
[Metabolism of the ischemic myocardium in non-insulin-dependent diabetes].
Topics: Aged; Aorta; Coronary Disease; Coronary Vessels; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterifi | 1989 |
Antilipolytic effect of insulin in non-insulin-dependent diabetes mellitus after conventional treatment with diet and sulfonylurea.
Topics: Adipose Tissue; Adult; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Glucose Tolerance Test; Gl | 1988 |
Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonest | 1987 |
Increased rate of Cori cycle in obese subjects with NIDDM and effect of weight reduction.
Topics: Body Composition; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Fasting; Fatty Ac | 1988 |
Mechanism of metformin action in non-insulin-dependent diabetes.
Topics: Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Tolerance Test; Gl | 1987 |
Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients.
Topics: Blood Glucose; C-Peptide; Chromatography, Gel; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; | 1985 |
Effects of Lunar Phases on Foot Temperature, Oxidative Stress, and Inflammation in Type 2 Diabetic Subjects.
Topics: Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Male; Moon; Ox | 2023 |
Effects of Lunar Phases on Foot Temperature, Oxidative Stress, and Inflammation in Type 2 Diabetic Subjects.
Topics: Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Male; Moon; Ox | 2023 |
Effects of Lunar Phases on Foot Temperature, Oxidative Stress, and Inflammation in Type 2 Diabetic Subjects.
Topics: Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Male; Moon; Ox | 2023 |
Effects of Lunar Phases on Foot Temperature, Oxidative Stress, and Inflammation in Type 2 Diabetic Subjects.
Topics: Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Male; Moon; Ox | 2023 |
Effects of lunar cycle on fasting plasma glucose, heart rate and blood pressure in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; Circadian Rhythm; Cross-Sectional Studies; Diabetes Mellitus, T | 2021 |